Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients

Caroline A Sabin, Ed Wilkins, Maurice Murphy, Martin Fisher, Annemiek de Ruiter, Philippa J Easterbrook, Clifford Leen, Emmanuel Vlahakis, Patricia A Cane, Xu Li, Deenan Pillay, UK Expanded Access Amprenavir Programme

Research output: Contribution to journalArticlepeer-review

Abstract

We have undertaken a study of virological responses to amprenavir-containing antiretroviral regimens, during the expanded access programme within the UK. Ninety-five HIV-1-infected patients were included for which virological and immunological follow-up was available for 75, and baseline drug resistance data available for 51. These were highly drug-experienced patients, having previously received a median of nine antiviral drugs, within all available classes. Eighty-eight percent of patients had a virological response to the new regimen, with a median maximal decline of 1.45 log10 copies/ml, and 34% of patients reached
Original languageEnglish
Pages (from-to)301-8
Number of pages8
JournalAntiviral Therapy
Volume8
Issue number4
Publication statusPublished - Aug 2003

Keywords

  • Adult
  • Anti-HIV Agents
  • Carbamates
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Female
  • Genotype
  • HIV Infections
  • HIV Protease
  • HIV Protease Inhibitors
  • HIV Reverse Transcriptase
  • HIV-1
  • Humans
  • Male
  • Mutation
  • Predictive Value of Tests
  • Reverse Transcriptase Inhibitors
  • Salvage Therapy
  • Sulfonamides
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients'. Together they form a unique fingerprint.

Cite this